

# VU Research Portal

## Biochemical markers in dementia

Verwey, N.A.

2010

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Verwey, N. A. (2010). *Biochemical markers in dementia: from mice to men*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

# Biochemical markers in dementia: from mice to men

## *Contents*

|  |     |
|--|-----|
| <b>Chapter 1 General introduction and aim of the thesis</b>                              |     |
| 1.1 General Introduction   | 10  |
| 1.2 Aims of thesis   | 14  |
| <b>Chapter 2 Production and characterization of mAbs against A<math>\beta</math></b>     |     |
| 2.1 Quantification of A $\beta$ 40 in CSF  | 17  |
| 2.2 IHC characterization of novel mAbs against the N-terminus of A $\beta$               | 35  |
| <b>Chapter 3 CSF measurements in AD: Clinical chemical properties</b>                    |     |
| 3.1 Variability in longitudinal CSF Tau and P-Tau measurements                           | 53  |
| 3.2 A $\beta$ 42, Tau and P-Tau as CSF biomarkers for the diagnosis of AD                | 63  |
| 3.3 A worldwide multicenter comparison of assays for CSF biomarkers in AD                | 73  |
| <b>Chapter 4 Biomarkers in the clinic</b>  |     |
| 4.1 Additional value of CSF A $\beta$ 40 in the differentiation of FTLD and SMC          | 83  |
| 4.2 Serum amyloid P component as biomarker in MCI and AD                                 | 93  |
| 4.3 Evaluation of plasma A $\beta$ 40 and A $\beta$ 42 as predictors of conversion to AD | 103 |
| <b>Chapter 5 Biomarkers in future</b>  |     |
| 5.1 New research criteria for AD diagnosis applied in a memory clinic population         | 107 |
| <b>Chapter 6 Summary, general discussion, and conclusion</b>                             | 117 |
| <b>Chapter 7</b>   | 127 |
| 7.1 Nederlandse samenvatting   |     |
| 7.2 Dankwoord  |     |
| 7.3 Publication list   |     |
| 7.4 Curriculum Vitae   |     |
| 7.5 References   |     |